You are using an unsupported browser. Please upgrade your browser to a newer version to get the best experience on DrugBank.
Identification
NameSalicylamide
Accession NumberDB08797
TypeSmall Molecule
GroupsApproved
DescriptionSalicylamide is the common name for the substance o-hydroxybenzamide, or amide of salicyl. Salicylamide is a non-prescription drug with analgesic and antipyretic properties. Its medicinal uses are similar to those of aspirin. Salicylamide is used in combination with both aspirin and caffeine in the over-the-counter pain remedies
Structure
Thumb
Synonyms
2-Carbamoylphenol
2-Carboxamidophenol
2-Hydroxybenzamide
o-hydroxybenzamide
OHB
Salicilamida
Salicylamidum
Salicylic acid amide
External Identifiers Not Available
Approved Prescription ProductsNot Available
Approved Generic Prescription ProductsNot Available
Approved Over the Counter ProductsNot Available
Unapproved/Other Products Not Available
International BrandsNot Available
Brand mixtures
NameLabellerIngredients
ExaprinHART Health
Green Guard Pain and Ache ReliefUnifirst First Aid Corporation
Medi First Pain ReliefUnifirst First Aid Corporation
Medi First Plus Pain ZapperUnifirst First Aid Corporation
Pain RelieverAdvanced First Aid, Inc.
Pain Stopper ExtraNorth Safety Products LLC
Pain Stoppers RegularNorth Safety Products LLC
Pain TerminatorProvision Medical Products
Zee Pain AidZee Medical Inc
SaltsNot Available
Categories
UNIIEM8BM710ZC
CAS number65-45-2
WeightAverage: 137.136
Monoisotopic: 137.047678473
Chemical FormulaC7H7NO2
InChI KeyInChIKey=SKZKKFZAGNVIMN-UHFFFAOYSA-N
InChI
InChI=1S/C7H7NO2/c8-7(10)5-3-1-2-4-6(5)9/h1-4,9H,(H2,8,10)
IUPAC Name
2-hydroxybenzamide
SMILES
NC(=O)C1=CC=CC=C1O
Taxonomy
DescriptionThis compound belongs to the class of organic compounds known as salicylamides. These are carboxamide derivatives of salicylic acid. Salicylic acid is the ortho-hydroxylated derivative of benzoic acid.
KingdomOrganic compounds
Super ClassBenzenoids
ClassBenzene and substituted derivatives
Sub ClassBenzoic acids and derivatives
Direct ParentSalicylamides
Alternative Parents
Substituents
  • Salicylamide
  • Benzamide
  • Benzoyl
  • Phenol
  • Vinylogous acid
  • Primary carboxylic acid amide
  • Carboxamide group
  • Carboxylic acid derivative
  • Hydrocarbon derivative
  • Organooxygen compound
  • Organonitrogen compound
  • Carbonyl group
  • Aromatic homomonocyclic compound
Molecular FrameworkAromatic homomonocyclic compounds
External Descriptors
Pharmacology
IndicationNot Available
PharmacodynamicsNot Available
Mechanism of actionNot Available
Related Articles
AbsorptionNot Available
Volume of distributionNot Available
Protein bindingNot Available
MetabolismNot Available
Route of eliminationNot Available
Half lifeNot Available
ClearanceNot Available
ToxicityOral, rat LD50: 1890 mg/kg
Affected organisms
  • Humans and other mammals
PathwaysNot Available
SNP Mediated EffectsNot Available
SNP Mediated Adverse Drug ReactionsNot Available
ADMET
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+0.9877
Blood Brain Barrier+0.9382
Caco-2 permeable+0.6048
P-glycoprotein substrateNon-substrate0.8565
P-glycoprotein inhibitor INon-inhibitor0.9817
P-glycoprotein inhibitor IINon-inhibitor0.9948
Renal organic cation transporterNon-inhibitor0.9178
CYP450 2C9 substrateNon-substrate0.8207
CYP450 2D6 substrateNon-substrate0.6203
CYP450 3A4 substrateNon-substrate0.7067
CYP450 1A2 substrateNon-inhibitor0.7061
CYP450 2C9 inhibitorNon-inhibitor0.952
CYP450 2D6 inhibitorNon-inhibitor0.9043
CYP450 2C19 inhibitorNon-inhibitor0.8779
CYP450 3A4 inhibitorNon-inhibitor0.8828
CYP450 inhibitory promiscuityLow CYP Inhibitory Promiscuity0.9144
Ames testNon AMES toxic0.9133
CarcinogenicityNon-carcinogens0.864
BiodegradationReady biodegradable0.7192
Rat acute toxicity2.1150 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.9867
hERG inhibition (predictor II)Non-inhibitor0.9468
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397 )
Pharmacoeconomics
ManufacturersNot Available
PackagersNot Available
Dosage forms
FormRouteStrength
Tabletoral
PricesNot Available
PatentsNot Available
Properties
StateSolid
Experimental Properties
PropertyValueSource
melting point142 °CPhysProp
boiling point181.5 °CPhysProp
water solubility2060 mg/L (at 25 °C)YALKOWSKY,SH & DANNENFELSER,RM (1992)
logP1.28HANSCH,C ET AL. (1995)
pKa8.37 (at 20 °C)KORTUM,G ET AL (1961)
Predicted Properties
PropertyValueSource
Water Solubility7.82 mg/mLALOGPS
logP0.74ALOGPS
logP1.17ChemAxon
logS-1.2ALOGPS
pKa (Strongest Acidic)8.21ChemAxon
pKa (Strongest Basic)-1.8ChemAxon
Physiological Charge0ChemAxon
Hydrogen Acceptor Count2ChemAxon
Hydrogen Donor Count2ChemAxon
Polar Surface Area63.32 Å2ChemAxon
Rotatable Bond Count1ChemAxon
Refractivity37.12 m3·mol-1ChemAxon
Polarizability13.22 Å3ChemAxon
Number of Rings1ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleYesChemAxon
MDDR-like RuleYesChemAxon
Spectra
Mass Spec (NIST)Not Available
Spectra
Spectrum TypeDescriptionSplash Key
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, NegativeNot Available
References
Synthesis Reference

Elijah J. Gold, Esther Babad, Lydia Peer, Wei K. Chang, “Preparation of (-)-5-(beta)-1-hydroxy-2-((beta)-1-methyl-3-phenylpropyl)aminoethyl) salicylamide.” U.S. Patent US4658060, issued November, 1979.

US4658060
General ReferencesNot Available
External Links
ATC CodesN02BA75N02BA05N02BA55
AHFS CodesNot Available
PDB EntriesNot Available
FDA labelNot Available
MSDSDownload (57 KB)
Interactions
Drug Interactions
Drug
AbciximabSalicylamide may increase the anticoagulant activities of Abciximab.
AcebutololSalicylamide may decrease the antihypertensive activities of Acebutolol.
AceclofenacThe risk or severity of adverse effects can be increased when Aceclofenac is combined with Salicylamide.
AcenocoumarolSalicylamide may increase the anticoagulant activities of Acenocoumarol.
Acetylsalicylic acidThe risk or severity of adverse effects can be increased when Acetylsalicylic acid is combined with Salicylamide.
AdapaleneThe risk or severity of adverse effects can be increased when Adapalene is combined with Salicylamide.
Alendronic acidThe risk or severity of adverse effects can be increased when Salicylamide is combined with Alendronic acid.
AliskirenSalicylamide may decrease the antihypertensive activities of Aliskiren.
AlprenololSalicylamide may decrease the antihypertensive activities of Alprenolol.
AlprostadilThe therapeutic efficacy of Alprostadil can be decreased when used in combination with Salicylamide.
AmikacinSalicylamide may decrease the excretion rate of Amikacin which could result in a lower serum level and potentially a reduction in efficacy.
AmilorideSalicylamide may decrease the antihypertensive activities of Amiloride.
AncrodSalicylamide may increase the anticoagulant activities of Ancrod.
AntipyrineThe risk or severity of adverse effects can be increased when Antipyrine is combined with Salicylamide.
Antithrombin III humanSalicylamide may increase the anticoagulant activities of Antithrombin III human.
ApixabanSalicylamide may increase the anticoagulant activities of Apixaban.
ApremilastThe risk or severity of adverse effects can be increased when Apremilast is combined with Salicylamide.
ArdeparinSalicylamide may increase the anticoagulant activities of Ardeparin.
ArgatrobanSalicylamide may increase the anticoagulant activities of Argatroban.
ArotinololSalicylamide may decrease the antihypertensive activities of Arotinolol.
AtenololSalicylamide may decrease the antihypertensive activities of Atenolol.
AzapropazoneThe risk or severity of adverse effects can be increased when Azapropazone is combined with Salicylamide.
AzelastineThe risk or severity of adverse effects can be increased when Azelastine is combined with Salicylamide.
Azilsartan medoxomilThe risk or severity of adverse effects can be increased when Azilsartan medoxomil is combined with Salicylamide.
BalsalazideSalicylamide may increase the nephrotoxic activities of Balsalazide.
BalsalazideThe risk or severity of adverse effects can be increased when Balsalazide is combined with Salicylamide.
BecaplerminSalicylamide may increase the anticoagulant activities of Becaplermin.
BefunololSalicylamide may decrease the antihypertensive activities of Befunolol.
BenazeprilThe risk or severity of adverse effects can be increased when Benazepril is combined with Salicylamide.
BendroflumethiazideThe therapeutic efficacy of Bendroflumethiazide can be decreased when used in combination with Salicylamide.
BenoxaprofenThe risk or severity of adverse effects can be increased when Benoxaprofen is combined with Salicylamide.
BetaxololSalicylamide may decrease the antihypertensive activities of Betaxolol.
BevantololSalicylamide may decrease the antihypertensive activities of Bevantolol.
BimatoprostThe therapeutic efficacy of Bimatoprost can be decreased when used in combination with Salicylamide.
BisoprololSalicylamide may decrease the antihypertensive activities of Bisoprolol.
BivalirudinSalicylamide may increase the anticoagulant activities of Bivalirudin.
BopindololSalicylamide may decrease the antihypertensive activities of Bopindolol.
BromfenacThe risk or severity of adverse effects can be increased when Bromfenac is combined with Salicylamide.
BufuralolSalicylamide may decrease the antihypertensive activities of Bufuralol.
BumetanideSalicylamide may decrease the diuretic activities of Bumetanide.
BupranololSalicylamide may decrease the antihypertensive activities of Bupranolol.
CandesartanThe risk or severity of adverse effects can be increased when Candesartan is combined with Salicylamide.
CandoxatrilThe risk or severity of adverse effects can be increased when Candoxatril is combined with Salicylamide.
CaptoprilThe risk or severity of adverse effects can be increased when Captopril is combined with Salicylamide.
Carboprost TromethamineThe therapeutic efficacy of Carboprost Tromethamine can be decreased when used in combination with Salicylamide.
CarprofenThe risk or severity of adverse effects can be increased when Carprofen is combined with Salicylamide.
CarteololSalicylamide may decrease the antihypertensive activities of Carteolol.
CarvedilolSalicylamide may decrease the antihypertensive activities of Carvedilol.
CastanospermineThe risk or severity of adverse effects can be increased when Castanospermine is combined with Salicylamide.
CelecoxibThe risk or severity of adverse effects can be increased when Celecoxib is combined with Salicylamide.
CeliprololSalicylamide may decrease the antihypertensive activities of Celiprolol.
CertoparinSalicylamide may increase the anticoagulant activities of Certoparin.
ChloroquineThe risk or severity of adverse effects can be increased when Chloroquine is combined with Salicylamide.
ChlorothiazideThe therapeutic efficacy of Chlorothiazide can be decreased when used in combination with Salicylamide.
ChlorthalidoneThe therapeutic efficacy of Chlorthalidone can be decreased when used in combination with Salicylamide.
CholestyramineCholestyramine can cause a decrease in the absorption of Salicylamide resulting in a reduced serum concentration and potentially a decrease in efficacy.
CilazaprilThe risk or severity of adverse effects can be increased when Cilazapril is combined with Salicylamide.
Citric AcidSalicylamide may increase the anticoagulant activities of Citric Acid.
ClodronateThe risk or severity of adverse effects can be increased when Salicylamide is combined with Clodronate.
ClonixinThe risk or severity of adverse effects can be increased when Salicylamide is combined with Clonixin.
CloprostenolThe therapeutic efficacy of Cloprostenol can be decreased when used in combination with Salicylamide.
ColesevelamColesevelam can cause a decrease in the absorption of Salicylamide resulting in a reduced serum concentration and potentially a decrease in efficacy.
ColestipolColestipol can cause a decrease in the absorption of Salicylamide resulting in a reduced serum concentration and potentially a decrease in efficacy.
CyclosporineSalicylamide may increase the nephrotoxic activities of Cyclosporine.
D-LimoneneThe risk or severity of adverse effects can be increased when Salicylamide is combined with D-Limonene.
Dabigatran etexilateSalicylamide may increase the anticoagulant activities of Dabigatran etexilate.
DalteparinSalicylamide may increase the anticoagulant activities of Dalteparin.
DanaparoidSalicylamide may increase the anticoagulant activities of Danaparoid.
DaunorubicinSalicylamide may decrease the excretion rate of Daunorubicin which could result in a lower serum level and potentially a reduction in efficacy.
DeferasiroxThe risk or severity of adverse effects can be increased when Salicylamide is combined with Deferasirox.
DesirudinSalicylamide may increase the anticoagulant activities of Desirudin.
DesmopressinThe risk or severity of adverse effects can be increased when Salicylamide is combined with Desmopressin.
DexketoprofenThe risk or severity of adverse effects can be increased when Dexketoprofen is combined with Salicylamide.
DextranSalicylamide may increase the anticoagulant activities of Dextran.
Dextran 40Salicylamide may increase the anticoagulant activities of Dextran 40.
Dextran 70Salicylamide may increase the anticoagulant activities of Dextran 70.
Dextran 75Salicylamide may increase the anticoagulant activities of Dextran 75.
DiclofenacThe risk or severity of adverse effects can be increased when Diclofenac is combined with Salicylamide.
DicoumarolSalicylamide may increase the anticoagulant activities of Dicoumarol.
DiflunisalThe risk or severity of adverse effects can be increased when Diflunisal is combined with Salicylamide.
DigoxinThe serum concentration of Digoxin can be increased when it is combined with Salicylamide.
DihydrostreptomycinSalicylamide may decrease the excretion rate of Dihydrostreptomycin which could result in a lower serum level and potentially a reduction in efficacy.
DinoprostoneThe therapeutic efficacy of Dinoprostone can be decreased when used in combination with Salicylamide.
DoxorubicinSalicylamide may decrease the excretion rate of Doxorubicin which could result in a lower serum level and potentially a reduction in efficacy.
DrospirenoneSalicylamide may increase the hyperkalemic activities of Drospirenone.
DroxicamThe risk or severity of adverse effects can be increased when Salicylamide is combined with Droxicam.
Edetic AcidSalicylamide may increase the anticoagulant activities of Edetic Acid.
EdoxabanSalicylamide may increase the anticoagulant activities of Edoxaban.
EnalaprilThe risk or severity of adverse effects can be increased when Enalapril is combined with Salicylamide.
EnalaprilatThe risk or severity of adverse effects can be increased when Enalaprilat is combined with Salicylamide.
EnoxaparinSalicylamide may increase the anticoagulant activities of Enoxaparin.
EpirizoleThe risk or severity of adverse effects can be increased when Salicylamide is combined with Epirizole.
EpirubicinSalicylamide may decrease the excretion rate of Epirubicin which could result in a lower serum level and potentially a reduction in efficacy.
EplerenoneSalicylamide may decrease the antihypertensive activities of Eplerenone.
EpoprostenolThe therapeutic efficacy of Epoprostenol can be decreased when used in combination with Salicylamide.
EprosartanThe risk or severity of adverse effects can be increased when Eprosartan is combined with Salicylamide.
EsmololSalicylamide may decrease the antihypertensive activities of Esmolol.
Etacrynic acidSalicylamide may decrease the diuretic activities of Etacrynic acid.
EtanerceptThe risk or severity of adverse effects can be increased when Etanercept is combined with Salicylamide.
Ethyl biscoumacetateSalicylamide may increase the anticoagulant activities of Ethyl biscoumacetate.
Etidronic acidThe risk or severity of adverse effects can be increased when Salicylamide is combined with Etidronic acid.
EtodolacThe risk or severity of adverse effects can be increased when Etodolac is combined with Salicylamide.
EtofenamateThe risk or severity of adverse effects can be increased when Salicylamide is combined with Etofenamate.
EtoricoxibThe risk or severity of adverse effects can be increased when Etoricoxib is combined with Salicylamide.
Evening primrose oilThe risk or severity of adverse effects can be increased when Salicylamide is combined with Evening primrose oil.
exisulindThe risk or severity of adverse effects can be increased when exisulind is combined with Salicylamide.
FenbufenThe risk or severity of adverse effects can be increased when Salicylamide is combined with Fenbufen.
FenoprofenThe risk or severity of adverse effects can be increased when Fenoprofen is combined with Salicylamide.
FloctafenineThe risk or severity of adverse effects can be increased when Floctafenine is combined with Salicylamide.
FlunixinThe risk or severity of adverse effects can be increased when Salicylamide is combined with Flunixin.
FlurbiprofenThe risk or severity of adverse effects can be increased when Flurbiprofen is combined with Salicylamide.
Folic AcidThe therapeutic efficacy of Folic Acid can be decreased when used in combination with Salicylamide.
Fondaparinux sodiumSalicylamide may increase the anticoagulant activities of Fondaparinux sodium.
ForasartanThe risk or severity of adverse effects can be increased when Forasartan is combined with Salicylamide.
FosinoprilThe risk or severity of adverse effects can be increased when Fosinopril is combined with Salicylamide.
FramycetinSalicylamide may decrease the excretion rate of Framycetin which could result in a lower serum level and potentially a reduction in efficacy.
FurosemideSalicylamide may decrease the diuretic activities of Furosemide.
GemeprostThe therapeutic efficacy of Gemeprost can be decreased when used in combination with Salicylamide.
GentamicinSalicylamide may decrease the excretion rate of Gentamicin which could result in a lower serum level and potentially a reduction in efficacy.
HaloperidolThe risk or severity of adverse effects can be increased when Salicylamide is combined with Haloperidol.
HeparinSalicylamide may increase the anticoagulant activities of Heparin.
HirulogSalicylamide may increase the anticoagulant activities of Hirulog.
HMPL-004The risk or severity of adverse effects can be increased when HMPL-004 is combined with Salicylamide.
HydralazineSalicylamide may decrease the antihypertensive activities of Hydralazine.
HydrochlorothiazideThe therapeutic efficacy of Hydrochlorothiazide can be decreased when used in combination with Salicylamide.
HydroflumethiazideThe therapeutic efficacy of Hydroflumethiazide can be decreased when used in combination with Salicylamide.
Hygromycin BSalicylamide may decrease the excretion rate of Hygromycin B which could result in a lower serum level and potentially a reduction in efficacy.
IbandronateThe risk or severity of adverse effects can be increased when Salicylamide is combined with Ibandronate.
IbuprofenThe risk or severity of adverse effects can be increased when Ibuprofen is combined with Salicylamide.
IbuproxamThe risk or severity of adverse effects can be increased when Salicylamide is combined with Ibuproxam.
IcatibantThe risk or severity of adverse effects can be increased when Icatibant is combined with Salicylamide.
IdarubicinSalicylamide may decrease the excretion rate of Idarubicin which could result in a lower serum level and potentially a reduction in efficacy.
IloprostThe therapeutic efficacy of Iloprost can be decreased when used in combination with Salicylamide.
IndapamideThe therapeutic efficacy of Indapamide can be decreased when used in combination with Salicylamide.
IndenololSalicylamide may decrease the antihypertensive activities of Indenolol.
IndomethacinThe risk or severity of adverse effects can be increased when Indomethacin is combined with Salicylamide.
IndoprofenThe risk or severity of adverse effects can be increased when Salicylamide is combined with Indoprofen.
IrbesartanThe risk or severity of adverse effects can be increased when Irbesartan is combined with Salicylamide.
IsoxicamThe risk or severity of adverse effects can be increased when Salicylamide is combined with Isoxicam.
KanamycinSalicylamide may decrease the excretion rate of Kanamycin which could result in a lower serum level and potentially a reduction in efficacy.
KebuzoneThe risk or severity of adverse effects can be increased when Salicylamide is combined with Kebuzone.
KetoprofenThe risk or severity of adverse effects can be increased when Ketoprofen is combined with Salicylamide.
KetorolacThe risk or severity of adverse effects can be increased when Ketorolac is combined with Salicylamide.
LabetalolSalicylamide may decrease the antihypertensive activities of Labetalol.
LeflunomideThe risk or severity of adverse effects can be increased when Leflunomide is combined with Salicylamide.
LepirudinSalicylamide may increase the anticoagulant activities of Lepirudin.
LevobunololSalicylamide may decrease the antihypertensive activities of Levobunolol.
LisinoprilThe risk or severity of adverse effects can be increased when Lisinopril is combined with Salicylamide.
LithiumThe serum concentration of Lithium can be increased when it is combined with Salicylamide.
LornoxicamThe risk or severity of adverse effects can be increased when Lornoxicam is combined with Salicylamide.
LosartanThe risk or severity of adverse effects can be increased when Losartan is combined with Salicylamide.
LoxoprofenThe risk or severity of adverse effects can be increased when Salicylamide is combined with Loxoprofen.
LubiprostoneThe therapeutic efficacy of Lubiprostone can be decreased when used in combination with Salicylamide.
LumiracoxibThe risk or severity of adverse effects can be increased when Lumiracoxib is combined with Salicylamide.
Magnesium salicylateThe risk or severity of adverse effects can be increased when Magnesium salicylate is combined with Salicylamide.
MasoprocolThe risk or severity of adverse effects can be increased when Masoprocol is combined with Salicylamide.
Meclofenamic acidThe risk or severity of adverse effects can be increased when Meclofenamic acid is combined with Salicylamide.
Mefenamic acidThe risk or severity of adverse effects can be increased when Mefenamic acid is combined with Salicylamide.
MeloxicamThe risk or severity of adverse effects can be increased when Meloxicam is combined with Salicylamide.
MesalazineSalicylamide may increase the nephrotoxic activities of Mesalazine.
MesalazineThe risk or severity of adverse effects can be increased when Mesalazine is combined with Salicylamide.
MetamizoleThe risk or severity of adverse effects can be increased when Metamizole is combined with Salicylamide.
MethotrexateThe serum concentration of Methotrexate can be increased when it is combined with Salicylamide.
MethyclothiazideThe therapeutic efficacy of Methyclothiazide can be decreased when used in combination with Salicylamide.
MetipranololSalicylamide may decrease the antihypertensive activities of Metipranolol.
MetolazoneThe therapeutic efficacy of Metolazone can be decreased when used in combination with Salicylamide.
MetoprololSalicylamide may decrease the antihypertensive activities of Metoprolol.
MetrizamideSalicylamide may decrease the excretion rate of Metrizamide which could result in a lower serum level and potentially a reduction in efficacy.
MisoprostolThe therapeutic efficacy of Misoprostol can be decreased when used in combination with Salicylamide.
MoexiprilThe risk or severity of adverse effects can be increased when Moexipril is combined with Salicylamide.
MorniflumateThe risk or severity of adverse effects can be increased when Morniflumate is combined with Salicylamide.
Mycophenolate mofetilThe risk or severity of adverse effects can be increased when Mycophenolate mofetil is combined with Salicylamide.
Mycophenolic acidThe risk or severity of adverse effects can be increased when Mycophenolic acid is combined with Salicylamide.
NabumetoneThe risk or severity of adverse effects can be increased when Nabumetone is combined with Salicylamide.
NadololSalicylamide may decrease the antihypertensive activities of Nadolol.
NadroparinSalicylamide may increase the anticoagulant activities of Nadroparin.
NaftifineThe risk or severity of adverse effects can be increased when Naftifine is combined with Salicylamide.
NaproxenThe risk or severity of adverse effects can be increased when Naproxen is combined with Salicylamide.
NCX 4016The risk or severity of adverse effects can be increased when NCX 4016 is combined with Salicylamide.
NeomycinSalicylamide may decrease the excretion rate of Neomycin which could result in a lower serum level and potentially a reduction in efficacy.
NepafenacThe risk or severity of adverse effects can be increased when Nepafenac is combined with Salicylamide.
NetilmicinSalicylamide may decrease the excretion rate of Netilmicin which could result in a lower serum level and potentially a reduction in efficacy.
Niflumic AcidThe risk or severity of adverse effects can be increased when Niflumic Acid is combined with Salicylamide.
NimesulideThe risk or severity of adverse effects can be increased when Nimesulide is combined with Salicylamide.
OlmesartanThe risk or severity of adverse effects can be increased when Olmesartan is combined with Salicylamide.
OlopatadineThe risk or severity of adverse effects can be increased when Olopatadine is combined with Salicylamide.
OlsalazineSalicylamide may increase the nephrotoxic activities of Olsalazine.
OlsalazineThe risk or severity of adverse effects can be increased when Olsalazine is combined with Salicylamide.
Omacetaxine mepesuccinateThe risk or severity of adverse effects can be increased when Salicylamide is combined with Omacetaxine mepesuccinate.
OmapatrilatThe risk or severity of adverse effects can be increased when Omapatrilat is combined with Salicylamide.
OrgoteinThe risk or severity of adverse effects can be increased when Salicylamide is combined with Orgotein.
OtamixabanSalicylamide may increase the anticoagulant activities of Otamixaban.
OxaprozinThe risk or severity of adverse effects can be increased when Oxaprozin is combined with Salicylamide.
OxprenololSalicylamide may decrease the antihypertensive activities of Oxprenolol.
OxyphenbutazoneThe risk or severity of adverse effects can be increased when Oxyphenbutazone is combined with Salicylamide.
PamidronateThe risk or severity of adverse effects can be increased when Salicylamide is combined with Pamidronate.
ParecoxibThe risk or severity of adverse effects can be increased when Parecoxib is combined with Salicylamide.
ParomomycinSalicylamide may decrease the excretion rate of Paromomycin which could result in a lower serum level and potentially a reduction in efficacy.
PenbutololSalicylamide may decrease the antihypertensive activities of Penbutolol.
Pentosan PolysulfateSalicylamide may increase the anticoagulant activities of Pentosan Polysulfate.
PerindoprilThe risk or severity of adverse effects can be increased when Perindopril is combined with Salicylamide.
PhenindioneSalicylamide may increase the anticoagulant activities of Phenindione.
PhenprocoumonSalicylamide may increase the anticoagulant activities of Phenprocoumon.
PhenylbutazoneThe risk or severity of adverse effects can be increased when Phenylbutazone is combined with Salicylamide.
PimecrolimusThe risk or severity of adverse effects can be increased when Pimecrolimus is combined with Salicylamide.
PindololSalicylamide may decrease the antihypertensive activities of Pindolol.
PiretanideSalicylamide may decrease the diuretic activities of Piretanide.
PirfenidoneThe risk or severity of adverse effects can be increased when Pirfenidone is combined with Salicylamide.
PiroxicamThe risk or severity of adverse effects can be increased when Piroxicam is combined with Salicylamide.
PlicamycinSalicylamide may decrease the excretion rate of Plicamycin which could result in a lower serum level and potentially a reduction in efficacy.
PolythiazideThe therapeutic efficacy of Polythiazide can be decreased when used in combination with Salicylamide.
PractololSalicylamide may decrease the antihypertensive activities of Practolol.
PralatrexateThe serum concentration of Pralatrexate can be increased when it is combined with Salicylamide.
ProbenecidThe serum concentration of Salicylamide can be increased when it is combined with Probenecid.
PropacetamolThe risk or severity of adverse effects can be increased when Salicylamide is combined with Propacetamol.
PropranololSalicylamide may decrease the antihypertensive activities of Propranolol.
Prostaglandin D2The therapeutic efficacy of Prostaglandin D2 can be decreased when used in combination with Salicylamide.
Protein CSalicylamide may increase the anticoagulant activities of Protein C.
ProtocatechualdehydeSalicylamide may increase the anticoagulant activities of Protocatechualdehyde.
PTC299The risk or severity of adverse effects can be increased when PTC299 is combined with Salicylamide.
PuromycinSalicylamide may decrease the excretion rate of Puromycin which could result in a lower serum level and potentially a reduction in efficacy.
QuinaprilThe risk or severity of adverse effects can be increased when Quinapril is combined with Salicylamide.
QuinethazoneThe therapeutic efficacy of Quinethazone can be decreased when used in combination with Salicylamide.
RamiprilThe risk or severity of adverse effects can be increased when Ramipril is combined with Salicylamide.
RescinnamineThe risk or severity of adverse effects can be increased when Rescinnamine is combined with Salicylamide.
ResveratrolThe risk or severity of adverse effects can be increased when Resveratrol is combined with Salicylamide.
ReviparinSalicylamide may increase the anticoagulant activities of Reviparin.
RibostamycinSalicylamide may decrease the excretion rate of Ribostamycin which could result in a lower serum level and potentially a reduction in efficacy.
RisedronateThe risk or severity of adverse effects can be increased when Salicylamide is combined with Risedronate.
RivaroxabanSalicylamide may increase the anticoagulant activities of Rivaroxaban.
RofecoxibThe risk or severity of adverse effects can be increased when Rofecoxib is combined with Salicylamide.
Salicylic acidThe risk or severity of adverse effects can be increased when Salicylic acid is combined with Salicylamide.
SalsalateThe risk or severity of adverse effects can be increased when Salsalate is combined with Salicylamide.
SaprisartanThe risk or severity of adverse effects can be increased when Saprisartan is combined with Salicylamide.
SaralasinThe risk or severity of adverse effects can be increased when Saralasin is combined with Salicylamide.
SeratrodastThe risk or severity of adverse effects can be increased when Seratrodast is combined with Salicylamide.
SotalolSalicylamide may decrease the antihypertensive activities of Sotalol.
SpectinomycinSalicylamide may decrease the excretion rate of Spectinomycin which could result in a lower serum level and potentially a reduction in efficacy.
SpiraprilThe risk or severity of adverse effects can be increased when Spirapril is combined with Salicylamide.
SpironolactoneSalicylamide may decrease the antihypertensive activities of Spironolactone.
SRT501The risk or severity of adverse effects can be increased when SRT501 is combined with Salicylamide.
StreptomycinSalicylamide may decrease the excretion rate of Streptomycin which could result in a lower serum level and potentially a reduction in efficacy.
StreptozocinSalicylamide may decrease the excretion rate of Streptozocin which could result in a lower serum level and potentially a reduction in efficacy.
SulfasalazineSalicylamide may increase the nephrotoxic activities of Sulfasalazine.
SulfasalazineThe risk or severity of adverse effects can be increased when Sulfasalazine is combined with Salicylamide.
SulindacThe risk or severity of adverse effects can be increased when Sulindac is combined with Salicylamide.
SulodexideSalicylamide may increase the anticoagulant activities of Sulodexide.
SuprofenThe risk or severity of adverse effects can be increased when Suprofen is combined with Salicylamide.
TacrolimusSalicylamide may increase the nephrotoxic activities of Tacrolimus.
TalniflumateThe risk or severity of adverse effects can be increased when Talniflumate is combined with Salicylamide.
TasosartanThe risk or severity of adverse effects can be increased when Tasosartan is combined with Salicylamide.
Technetium Tc-99m MedronateThe risk or severity of adverse effects can be increased when Salicylamide is combined with Technetium Tc-99m Medronate.
TelmisartanThe risk or severity of adverse effects can be increased when Telmisartan is combined with Salicylamide.
TemocaprilThe risk or severity of adverse effects can be increased when Temocapril is combined with Salicylamide.
TenofovirThe risk or severity of adverse effects can be increased when Salicylamide is combined with Tenofovir.
TenoxicamThe risk or severity of adverse effects can be increased when Tenoxicam is combined with Salicylamide.
TepoxalinThe risk or severity of adverse effects can be increased when Salicylamide is combined with Tepoxalin.
TeriflunomideThe risk or severity of adverse effects can be increased when Salicylamide is combined with Teriflunomide.
Tiaprofenic acidThe risk or severity of adverse effects can be increased when Tiaprofenic acid is combined with Salicylamide.
TiludronateThe risk or severity of adverse effects can be increased when Salicylamide is combined with Tiludronate.
TimololSalicylamide may decrease the antihypertensive activities of Timolol.
TobramycinSalicylamide may decrease the excretion rate of Tobramycin which could result in a lower serum level and potentially a reduction in efficacy.
Tolfenamic AcidThe risk or severity of adverse effects can be increased when Salicylamide is combined with Tolfenamic Acid.
TolmetinThe risk or severity of adverse effects can be increased when Tolmetin is combined with Salicylamide.
TorasemideSalicylamide may decrease the diuretic activities of Torasemide.
TrandolaprilThe risk or severity of adverse effects can be increased when Trandolapril is combined with Salicylamide.
TranilastThe risk or severity of adverse effects can be increased when Tranilast is combined with Salicylamide.
TravoprostThe therapeutic efficacy of Travoprost can be decreased when used in combination with Salicylamide.
TreprostinilThe risk or severity of adverse effects can be increased when Treprostinil is combined with Salicylamide.
TriamtereneSalicylamide may decrease the antihypertensive activities of Triamterene.
TrichlormethiazideThe therapeutic efficacy of Trichlormethiazide can be decreased when used in combination with Salicylamide.
Trisalicylate-cholineThe risk or severity of adverse effects can be increased when Trisalicylate-choline is combined with Salicylamide.
ValdecoxibThe risk or severity of adverse effects can be increased when Valdecoxib is combined with Salicylamide.
ValsartanThe risk or severity of adverse effects can be increased when Valsartan is combined with Salicylamide.
VancomycinThe serum concentration of Vancomycin can be increased when it is combined with Salicylamide.
WarfarinSalicylamide may increase the anticoagulant activities of Warfarin.
XimelagatranSalicylamide may increase the anticoagulant activities of Ximelagatran.
ZaltoprofenThe risk or severity of adverse effects can be increased when Zaltoprofen is combined with Salicylamide.
ZileutonThe risk or severity of adverse effects can be increased when Zileuton is combined with Salicylamide.
Zoledronic acidThe risk or severity of adverse effects can be increased when Salicylamide is combined with Zoledronic acid.
ZomepiracThe risk or severity of adverse effects can be increased when Zomepirac is combined with Salicylamide.
Food InteractionsNot Available
Comments
comments powered by Disqus
Drug created on October 08, 2010 16:10 / Updated on August 17, 2016 12:24